Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr — Boston, Massachusetts

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 59/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr has participated in 2 clinical trials.

Therapeutic areas: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 59/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr?

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr has a Crixeo Trust Score of 59/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr conducted?

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr has 2 clinical trials on record. Their work covers Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia.

Is Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr accredited by Crixeo Health?

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.